TBC 190
Alternative Names: TBC-190Latest Information Update: 24 May 2024
At a glance
- Originator FibroBiologics
- Class Antineoplastics; Fibroblast cell therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer